Heterogeneity of breast cancer: Etiology and clinical relevance

Clinical and Translational Oncology

Volumn 13, Issue 11, 2011, Pages 767-773

  Almendro, Vanessa ^a   Fuster, Gemma ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer; Chemotherapy; Heterogeneity; Stem like cells

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STEM CELL; CELL SELECTION; CELL SUBPOPULATION; DISEASE ASSOCIATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; MOLECULAR EVOLUTION; NONHUMAN; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION;

EID: 84856050530     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0731-9     Document Type: Article

References (57)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across fi ve continents: Defi ning priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150 (Pubitemid 46655601)
2. Marusyk A, Polyak K (2010) Tumor heterogeneity: Causes and consequences. Biochim Biophys Acta 1805:105-117
3. Benetkiewicz M, Piotrowski A, Diaz De Stahl T et al (2006) Chromosome 22 array-CGH profi ling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int J Oncol 29:935-945
4. Tavassoéli FA, Devilee P (2003) Classification of tumours. World Health Organization, IARC, WHO No 4
5. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
6. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874 (Pubitemid 32878711)
7. Herschkowitz JI, Simin K, Weigman VJ et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:R76
8. Prat A, Parker JS, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68
9. Polyak K, Kalluri R (2010) The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2:a003244
10. Visvader JE (2009) Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 23:2563-2577
11. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111 (Pubitemid 33041634)
12. Lim E, Vaillant F, Wu D et al (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907-913
13. Polyak K (2007) Breast cancer: Origins and evolution. J Clin Invest 117:3155-3163 (Pubitemid 350096968)
14. Visvader JE (2011) Cells of origin in cancer. Nature 469:314-322
15. Korsching E, Packeisen J, Agelopoulos K et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82:1525-1533 (Pubitemid 35332911)
16. Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715 (Pubitemid 351636299)
17. Chaffer CL, Brueckmann I, Scheel C et al (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 108:7950-7955
18. Broeks A, Schmidt MK, Sherman ME et al (2011) Low penetrance breast cancer susceptibility loci are associated with specifi c breast tumor subtypes: Findings from the Breast Cancer Association Consortium. Hum Mol Genet 20:3289-3303
19. Welcsh PL, King MC (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713 (Pubitemid 32331579)
20. Liu S, Ginestier C, Charafe-Jauffret E et al (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 105:1680-1685 (Pubitemid 351346574)
21. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819 (Pubitemid 39331153)
22. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423 (Pubitemid 36842560)
23. Palacios J, Honrado E, Osorio A et al (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90:5-14 (Pubitemid 40486996)
24. Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basallike (cyclin E high/p27 low/p53+/glomeruloid- microvascular- proliferation+) phenotype of BRCA1- related breast cancer. Cancer Res 64:830-835
25. Molyneux G, Geyer FC, Magnay FA et al (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7:403-417
26. Proia TA, Keller PJ, Gupta PB et al (2011) Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8:149-163
27. Michor F, Polyak K (2010) The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila) 3:1361-1364
28. Cohnheim V (1875) Congenitales, quergestreiftes muskelsarkom der nieren. Virchows Arch Pathol Anat Physiol Klin Med 65:64-69
29. Makino S (1956) Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann N Y Acad Sci 63:818-830
30. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737 (Pubitemid 27298715)
31. Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-3988 (Pubitemid 36418143)
32. Pece S, Tosoni D, Confalonieri S et al (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140:62-73
33. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L et al (2007) Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol 177:87-101 (Pubitemid 46588404)
34. Clayton H, Titley I, Vivanco M (2004) Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res 297:444-460 (Pubitemid 38798406)
35. Meyer MJ, Fleming JM, Lin AF et al (2010) CD44posCD49fhiCD133/2hi defines xenograftinitiating cells in estrogen receptor-negative breast cancer. Cancer Res 70:4624-4633
36. Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567 (Pubitemid 350056407)
37. Shipitsin M, Campbell LL, Argani P et al (2007) Molecular defi nition of breast tumor heterogeneity. Cancer Cell 11:259-273 (Pubitemid 46349843)
38. Quintana E, Shackleton M, Sabel MS et al (2008) Effi cient tumour formation by single human melanoma cells. Nature 456:593-598
39. Iliopoulos D, Hirsch HA, Wang G, Struhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 108:1397-1402
40. Marotta LL, Almendro V, Marusyk A et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44CD24 stem cell-like breast cancer cells in human tumors. J Clin Invest 121:2723-2735
41. Louie E, Nik S, Chen JS et al (2010) Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 12:R94
42. Mathieu J, Zhang Z, Zhou W et al (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71:4640-4652
43. Park SY, Lee HE, Li H et al (2010) Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16:876-887
44. Honeth G, Bendahl PO, Ringner M et al (2008) The CD44+/CD24- phenotype is enriched in basal- like breast tumors. Breast Cancer Res 10:R53
45. Pece S, Tosoni D, Confalonieri S et al (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140:62-73
46. Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:924-935 (Pubitemid 44862677)
47. Hu M, Yao J, Carroll DK et al (2008) Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13:394-406 (Pubitemid 351609443)
48. Hu M, Polyak K (2008) Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer 44:2760-2765
49. Karnoub AE, Dash AB, Vo AP et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563 (Pubitemid 47525152)
50. Scheel C, Eaton EN, Li SH et al (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145:926-940
51. Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2/neu in breast cancer: A rare event. Breast J 13:122-129 (Pubitemid 46280606)
52. Brunelli M, Manfrin E, Martignoni G et al (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: Evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131:678-682
53. Cottu PH, Asselah J, Lae M et al (2008) Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 19:595-597
54. Kalinsky K, Heguy A, Bhanot UK et al (2011) PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 129:635-643
55. Gerlinger M, Swanton C (2010) How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 103:1139-1143
56. Creighton CJ, Li X, Landis M et al (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106:13820-13825
57. Lee HE, Kim JH, Kim YJ et al (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104:1730-1738